GLOW Blend Explained: GHK-Cu, BPC-157, TB-500
GLOW brings three research peptides together. A careful look at what each component is studied for, and why blend evidence is not the same as single-compound evidence.
Read articleA plain-language look at the regulatory context for research-use peptides in Australia and what labs should verify when sourcing compounds.
Research peptides sit in a genuine legal grey zone in Australia: legal to possess for laboratory use, but only within TGA rules that trip up more labs than most researchers realise.
In Australia, research‑only peptides are legal to possess, but only under strict conditions set by the Therapeutic Goods Administration (TGA). The TGA distinguishes between therapeutic products that can be marketed to patients and research‑only materials that are limited to laboratory work.
Peptides are short chains of amino acids that can act like hormones, signalling molecules or enzyme modifiers. Their ability to target specific cellular pathways makes them valuable tools for investigating metabolism, tissue repair, and receptor biology. Because they can be synthesised relatively simply, many Australian labs are turning to custom‑made peptides to explore new scientific questions.
Before ordering a peptide, most investigators want to know whether the compound fits within the legal framework. The answers guide procurement, storage and documentation practices.
The TGA operates under the Therapeutic Goods Act, which governs all products that could affect human health. Peptides that are not approved for clinical use are listed on the Australian Register of Therapeutic Goods (ARTG) only if they have a therapeutic licence. Those that lack such a licence may be supplied as “research‑only” or “RUO” items, provided they are not advertised or sold for human consumption.
A peptide is deemed a therapeutic product when it has been evaluated for safety and efficacy in humans. If the same molecule is supplied solely for experimental work, the supplier must label it clearly as research‑only and ensure the buyer acknowledges the RUO status. Importing a research‑only peptide still requires a TGA import permit, because the border agency monitors all therapeutic‑goods shipments. Laboratories must retain the permit, the supplier’s certificate of analysis, and a signed declaration that the material will not be used in any clinical or animal‑testing context without further approval.
Recent TGA enforcement actions illustrate how the rules are applied. In several cases, customs flagged peptide shipments that lacked proper import documentation, resulting in temporary seizure until the supplier provided the required RUO declaration. Laboratory audits have also identified instances where research peptides were stored alongside consumable reagents, prompting corrective notices that emphasise physical segregation and clear labelling.
Compared with the United States, where the Food and Drug Administration (FDA) allows “research chemicals” to be sold with minimal oversight, Australia’s TGA adopts a tighter gate‑keeping approach. The European Union similarly requires an import licence for non‑clinical peptides, but individual member states may have varying tolerances for on‑site use. These differences affect how quickly researchers can obtain material and what paperwork is needed.
Despite clear guidelines, some practical questions remain unanswered. The TGA has not published detailed criteria for when a peptide transitions from RUO to therapeutic status, leaving suppliers to interpret the boundary. Guidance on acceptable storage conditions for RUO peptides in shared facilities is limited, as is advice on how to document cross‑institution transfers without breaching the ARTG rules.
Operator’s desk: Remember that compliance is a continuous process—not a one‑time paperwork task. Regular internal reviews help ensure that any changes in supplier status or TGA policy are reflected promptly in your lab’s SOPs.
All information presented here is for research and educational purposes only. Research peptides are not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be used for human or animal consumption. Ensure you follow all TGA regulations and institutional policies when handling these materials.
Links lead to the original paper, DOI record, or open-access full text where available.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.

GLOW brings three research peptides together. A careful look at what each component is studied for, and why blend evidence is not the same as single-compound evidence.
Read article
An overview of SS-31, its relationship with cardiolipin in mitochondrial membranes, and how laboratory findings differ from clinical claims.
Read article
The history of DSIP in sleep research, the small human studies that exist, and the limits of the current evidence base.
Read articleA comparison of three compounds frequently studied in tissue models, how their research backgrounds differ, and why they are often examined together.
Read articleTell us what you need. An email address is required so we can reply.